David Silberman is the CFO, Treasurer & Sec. at Oramed Pharmaceuticals, Inc.
As the CFO y Treasurer & Sec. of Oramed Pharmaceuticals, Inc, the total compensation of Mr Silberman at Oramed Pharmaceuticals, Inc is $182,525. There are 8 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of $1,551,100.
Mr Silberman is 38, he's been the CFO y Treasurer & Sec. of Oramed Pharmaceuticals, Inc since . There are 13 older and 1 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
David's mailing address filed with the SEC is 20 MAMILLA AVENUE, , JERUSALEM, L3, 9414904.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank y Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: